Revive Therapeutics (CSE: RVV) has completed its oral thin film strip product for psilocybin after several months of prototyping. The company made the announcement this morning that the product, developed via a research partnership with Reed Research Group from the University of Wisconsin-Madison, has been completed with several dosage ranges available.
The oral thin film strip products are capable of containing psilocybin dosages ranging from 1 mg to that of 20 mg. Current technical and scientific data is being processed on the product, however it is said to have demonstrated a sufficient tensile strength of the film, as well as positive results in terms of dissolution and disintegration and rate of dosage release from the composite.
The product is being treated as a unique delivery platform for therapeutic dosages ranging from 1 to 20 mg of psilocybin within the mouth. The orally dissolvable thin film provides benefits over other delivery methods in that it features rapid onset of action to the bloodstream, requires no chewing, swallowing or even water, while enabling accurate dosing and tasteful options.
“We are very pleased to have achieved this development milestone of our orally dissolvable thin film strip for psilocybin, which can be used in FDA human clinical studies and as a unique product for medical use in states where psilocybin therapy use is permitted, such as Oregon following the passage of Measure 109. .. Also, we are in a position to begin partnering with life sciences companies seeking to add unique offerings in their psychedelic-based product pipeline and with companies operating in the U.S. where psilocybin therapy use is legal.”
Michael Frank, CEO of Revive
The company is currently preparing to scale for manufacturing for future clinical studies now that the prototypes have been finalized. The product is expected to be used in future clinical studies involving the use of psilocybin and other psychedelic-based medicines.
Revive Therapeutics last traded at $0.18 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
